Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13559754 | 0.87 | TP53 (0.48) | KCNH2TP53ENPP2THRBLMNA | |
| SCHEMBL13559750 | 0.82 | KCNH2 (0.51) | KCNH2SPHK1 | |
| SCHEMBL13559746 | 0.81 | KCNH2 (0.69) | KCNH2SPHK1 | |
| SCHEMBL6880434 | 0.80 | DRD4 (0.47) | KCNH2 | |
| SCHEMBL13559753 | 0.80 | KCNH2 (0.55) | KCNH2TP53ENPP2THRBLMNA | |
| SCHEMBL13479276 | 0.76 | SPHK1 (0.64) | SPHK1 | |
| SCHEMBL13479278 | 0.76 | SPHK1 (0.64) | SPHK1 | |
| SCHEMBL13508794 | 0.76 | KCNH2 (0.69) | KCNH2SPHK1LMNAMAPTTDP1 | |
| SCHEMBL13186674 | 0.76 | KCNH2 (0.78) | KCNH2SPHK1LMNAMAPTTDP1 | |
| SCHEMBL13187011 | 0.76 | KCNH2 (0.69) | KCNH2SPHK1LMNAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975247-B2 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NSUN3, RNGTT, NSUN2 | KCNH2 4544/4885TP53 4482/4885SPHK1 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.